These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 7695276

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin.
    Tomioka H, Saito H, Sato K.
    Antimicrob Agents Chemother; 1993 Jun; 37(6):1259-63. PubMed ID: 8392307
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [In vitro antimycobacterial activity of a new quinolone, T-3761].
    Tomioka H, Sato K, Saito H.
    Kekkaku; 1995 Feb; 70(2):97-101. PubMed ID: 7699982
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cross-resistance analysis for DU-6859a, a new fluoroquinolone, compared to six structurally similar compounds (ciprofloxacin, clinafloxacin, fleroxacin, levofloxacin, ofloxacin, and sparfloxacin).
    Cormican MG, Marshall SA, Jones RN.
    Diagn Microbiol Infect Dis; 1995 Jan; 21(1):51-4. PubMed ID: 7789097
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [In vitro antimycobacterial activities of a new quinolone, balofloxacin].
    Kawahara S, Tada A, Nagare H.
    Kekkaku; 2001 Jan; 76(1):29-31. PubMed ID: 11211780
    [Abstract] [Full Text] [Related]

  • 13. In vitro activity of DU-6859a, a new fluorocyclopropyl quinolone.
    Marshall SA, Jones RN.
    Antimicrob Agents Chemother; 1993 Dec; 37(12):2747-53. PubMed ID: 8109948
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Activities of three investigational fluoroquinolones (BAY y 3118, DU-6859a, and clinafloxacin) against Neisseria gonorrhoeae isolates with diminished susceptibilities to ciprofloxacin and ofloxacin.
    Carlyn CJ, Doyle LJ, Knapp CC, Ludwig MD, Washington JA.
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1606-8. PubMed ID: 7492114
    [Abstract] [Full Text] [Related]

  • 18. Bactericidal activity of the new 4-quinolones DU-6859a and DV-7751a.
    Morrissey I, Smith JT.
    J Med Microbiol; 1995 Jul; 43(1):4-8. PubMed ID: 7608954
    [Abstract] [Full Text] [Related]

  • 19. Comparative in vitro and in vivo activity of fleroxacin and ofloxacin against various mycobacteria.
    Tomioka H, Sato K, Saito H.
    Tubercle; 1991 Sep; 72(3):176-80. PubMed ID: 1771676
    [Abstract] [Full Text] [Related]

  • 20. CI-960 (PD127391 or AM-1091), sparfloxacin, WIN 57273, and isepamicin activity against clinical isolates of Mycobacterium avium-intracellularae complex, M. chelonae, and M. fortuitum.
    Barrett MS, Jones RN, Erwin ME, Koontz FP.
    Diagn Microbiol Infect Dis; 1992 Feb; 15(2):169-71. PubMed ID: 1315233
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.